Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma.

Adam Wanner, Gabor Horvath, Jorge L. Brieva, Sunil D. Kumar, Eliana Mendes

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Inhaled glucocorticosteroids (corticosteroids) continue to be the standard treatment for nonexacerbated asthma because of their anti-inflammatory actions. These include effects on the airway vasculature, which participates in the inflammatory process. Corticosteroids are now known to have genomic as well as nongenomic effects that involve different mechanisms of action. The genomic vascular effects of inhaled corticosteroids include a decrease in airway wall hypervascularity (inhibition of angiogenesis), reversal of the increased airway blood flow, and inhibition of vascular hyperpermeability and leukocyte recruitment. In addition, inhaled corticosteroids decrease airway blood flow acutely (within minutes) and reversibly through a nongenomic action that involves noradrenergic neurotransmission. This effect is likely related to the binding of inhaled corticosteroids to the plasma membrane of and the inhibition of the extraneuronal monoamine transporter on airway vascular smooth muscle cells, thereby increasing norepinephrine concentrations at alpha(1)-adrenoceptors and causing airway vascular smooth muscle contraction and a decrease in airway blood flow. Inasmuch as vascular hyperperfusion is a manifestation of airway inflammation, the acute vasoconstriction could also be considered an anti-inflammatory effect of inhaled corticosteroids.

Original languageEnglish
Pages (from-to)235-238
Number of pages4
JournalProc Am Thorac Soc
Volume1
Issue number3
StatePublished - Dec 1 2004

Fingerprint

Adrenal Cortex Hormones
Asthma
Blood Vessels
Vascular Smooth Muscle
Anti-Inflammatory Agents
Muscle Contraction
Vasoconstriction
Synaptic Transmission
Adrenergic Receptors
Smooth Muscle Myocytes
Norepinephrine
Leukocytes
Cell Membrane
Inflammation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology
  • Cell Biology

Cite this

Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. / Wanner, Adam; Horvath, Gabor; Brieva, Jorge L.; Kumar, Sunil D.; Mendes, Eliana.

In: Proc Am Thorac Soc, Vol. 1, No. 3, 01.12.2004, p. 235-238.

Research output: Contribution to journalArticle

Wanner, Adam ; Horvath, Gabor ; Brieva, Jorge L. ; Kumar, Sunil D. ; Mendes, Eliana. / Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. In: Proc Am Thorac Soc. 2004 ; Vol. 1, No. 3. pp. 235-238.
@article{165795a66b4e4cecb2f0cac698dd60b8,
title = "Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma.",
abstract = "Inhaled glucocorticosteroids (corticosteroids) continue to be the standard treatment for nonexacerbated asthma because of their anti-inflammatory actions. These include effects on the airway vasculature, which participates in the inflammatory process. Corticosteroids are now known to have genomic as well as nongenomic effects that involve different mechanisms of action. The genomic vascular effects of inhaled corticosteroids include a decrease in airway wall hypervascularity (inhibition of angiogenesis), reversal of the increased airway blood flow, and inhibition of vascular hyperpermeability and leukocyte recruitment. In addition, inhaled corticosteroids decrease airway blood flow acutely (within minutes) and reversibly through a nongenomic action that involves noradrenergic neurotransmission. This effect is likely related to the binding of inhaled corticosteroids to the plasma membrane of and the inhibition of the extraneuronal monoamine transporter on airway vascular smooth muscle cells, thereby increasing norepinephrine concentrations at alpha(1)-adrenoceptors and causing airway vascular smooth muscle contraction and a decrease in airway blood flow. Inasmuch as vascular hyperperfusion is a manifestation of airway inflammation, the acute vasoconstriction could also be considered an anti-inflammatory effect of inhaled corticosteroids.",
author = "Adam Wanner and Gabor Horvath and Brieva, {Jorge L.} and Kumar, {Sunil D.} and Eliana Mendes",
year = "2004",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "235--238",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma.

AU - Wanner, Adam

AU - Horvath, Gabor

AU - Brieva, Jorge L.

AU - Kumar, Sunil D.

AU - Mendes, Eliana

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Inhaled glucocorticosteroids (corticosteroids) continue to be the standard treatment for nonexacerbated asthma because of their anti-inflammatory actions. These include effects on the airway vasculature, which participates in the inflammatory process. Corticosteroids are now known to have genomic as well as nongenomic effects that involve different mechanisms of action. The genomic vascular effects of inhaled corticosteroids include a decrease in airway wall hypervascularity (inhibition of angiogenesis), reversal of the increased airway blood flow, and inhibition of vascular hyperpermeability and leukocyte recruitment. In addition, inhaled corticosteroids decrease airway blood flow acutely (within minutes) and reversibly through a nongenomic action that involves noradrenergic neurotransmission. This effect is likely related to the binding of inhaled corticosteroids to the plasma membrane of and the inhibition of the extraneuronal monoamine transporter on airway vascular smooth muscle cells, thereby increasing norepinephrine concentrations at alpha(1)-adrenoceptors and causing airway vascular smooth muscle contraction and a decrease in airway blood flow. Inasmuch as vascular hyperperfusion is a manifestation of airway inflammation, the acute vasoconstriction could also be considered an anti-inflammatory effect of inhaled corticosteroids.

AB - Inhaled glucocorticosteroids (corticosteroids) continue to be the standard treatment for nonexacerbated asthma because of their anti-inflammatory actions. These include effects on the airway vasculature, which participates in the inflammatory process. Corticosteroids are now known to have genomic as well as nongenomic effects that involve different mechanisms of action. The genomic vascular effects of inhaled corticosteroids include a decrease in airway wall hypervascularity (inhibition of angiogenesis), reversal of the increased airway blood flow, and inhibition of vascular hyperpermeability and leukocyte recruitment. In addition, inhaled corticosteroids decrease airway blood flow acutely (within minutes) and reversibly through a nongenomic action that involves noradrenergic neurotransmission. This effect is likely related to the binding of inhaled corticosteroids to the plasma membrane of and the inhibition of the extraneuronal monoamine transporter on airway vascular smooth muscle cells, thereby increasing norepinephrine concentrations at alpha(1)-adrenoceptors and causing airway vascular smooth muscle contraction and a decrease in airway blood flow. Inasmuch as vascular hyperperfusion is a manifestation of airway inflammation, the acute vasoconstriction could also be considered an anti-inflammatory effect of inhaled corticosteroids.

UR - http://www.scopus.com/inward/record.url?scp=19644362654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19644362654&partnerID=8YFLogxK

M3 - Article

C2 - 16113440

AN - SCOPUS:19644362654

VL - 1

SP - 235

EP - 238

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 3

ER -